

Christopher J Sweeney Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2585435/publications.pdf>

Version: 2024-02-01

244
papers

14,065
citations

31949

53
h-index

22808

112
g-index

246
all docs

246
docs citations

246
times ranked

14283
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 737-746.	13.9	2,112
2	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
3	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1087.	0.8	702
4	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
5	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 412-419.	0.8	405
6	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	0.8	362
7	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
8	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. <i>Blood</i> , 2007, 110, 4427-4435.	0.6	357
9	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3097-3104.	0.8	327
10	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
11	Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. <i>Journal of Clinical Oncology</i> , 2006, 24, 3451-3457.	0.8	234
12	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. <i>Journal of Clinical Oncology</i> , 2014, 32, 1889-1894.	0.8	229
13	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 115-124.	0.9	203
14	Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. <i>Journal of Clinical Oncology</i> , 2011, 29, 1525-1530.	0.8	180
15	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
16	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. <i>European Urology</i> , 2018, 73, 847-855.	0.9	174
17	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATentia150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 131-142.	6.3	167
18	Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 220-231.	0.5	164

#	ARTICLE	IF	CITATIONS
37	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
38	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. <i>Urology</i> , 2014, 84, 386-392.	0.5	86
39	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	0.8	83
40	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
41	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1285-1291.	0.8	81
42	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. <i>Cancer</i> , 2002, 94, 104-110.	2.0	79
43	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
44	A water soluble parthenolide analog suppresses <i>in vivo</i> tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF- κ B and generating reactive oxygen species. <i>International Journal of Cancer</i> , 2011, 128, 2481-2494.	2.3	72
45	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1088-1095.	0.8	72
46	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70
47	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 345-351.	0.8	69
48	Elevated IL-8, TNF- α , and MCP-1 in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) are associated with shorter time to castration resistance and overall survival. <i>Prostate</i> , 2014, 74, 820-828.	1.2	66
49	Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015, 116, 358-365.	1.3	66
50	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3018-3028.	0.8	63
51	A water-soluble parthenolide analogue suppresses <i>in vivo</i> prostate cancer growth by targeting NF- κ B and generating reactive oxygen species. <i>Prostate</i> , 2010, 70, 1074-1086.	1.2	60
52	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
53	Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. <i>Cancer</i> , 2017, 123, 1536-1544.	2.0	57
54	â€œGotta Catch 'em Allâ€, or Do We? Pokemet Approach to Metastatic Prostate Cancer. <i>European Urology</i> , 2017, 72, 1-3.	0.9	56

#	ARTICLE	IF	CITATIONS
55	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
56	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e7-18.e13.	0.8	53
57	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. <i>Journal of Clinical Investigation</i> , 2018, 128, 2979-2995.	3.9	53
58	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
59	<i>HSD3B1</i> Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, e196496.	3.4	50
60	Evaluation of HER-2/neu expression in prostatic adenocarcinoma. <i>Cancer</i> , 2002, 95, 1650-1655.	2.0	49
61	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 420-427.	2.0	49
62	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. <i>Journal of Clinical Oncology</i> , 2017, 35, 402-402.	0.8	49
63	Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e189-e195.	0.9	46
64	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. <i>Cancer</i> , 2016, 122, 3127-3135.	2.0	46
65	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	1.3	45
66	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. <i>Prostate</i> , 2006, 66, 1498-1511.	1.2	44
67	A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4513-4520.	0.8	44
68	Prostate cancer therapy: going forwards by going backwards. <i>Lancet Oncology</i> , The, 2013, 14, 104-105.	5.1	43
69	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (<i>CHEK2</i>) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	3.4	43
70	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	1.3	42
71	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 828-835.	0.4	40
72	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1736-1744.	1.9	39

#	ARTICLE	IF	CITATIONS
73	Sequencing current therapies in the treatment of metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 332-340.	3.4	38
74	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 488-498.	1.6	38
75	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. <i>Cancer</i> , 2018, 124, 925-933.	2.0	38
76	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
77	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
78	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4503-4503.	0.8	35
79	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	7.7	34
80	Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. <i>Prostate</i> , 2014, 74, 225-234.	1.2	33
81	Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF- κ B and Split-Dose Repair. <i>Radiation Research</i> , 2007, 168, 689-697.	0.7	32
82	A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 345-356.	1.1	32
83	Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues <i>In Vivo</i> . <i>Radiation Research</i> , 2017, 187, 501-512.	0.7	32
84	Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 714-720.	0.8	31
85	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 676-676.	0.8	30
86	Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 410-412.	0.9	29
87	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. <i>Journal of Clinical Oncology</i> , 2019, 37, 765-769.	0.8	29
88	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 837-846.	0.8	29
89	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004.	0.8	29
90	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28

#	ARTICLE	IF	CITATIONS
91	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	2.0	27
92	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3004-3004.	0.8	27
93	Computational Reconstruction of NF- κ B Pathway Interaction Mechanisms during Prostate Cancer. <i>PLoS Computational Biology</i> , 2016, 12, e1004820.	1.5	27
94	Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer. <i>Pancreas</i> , 2008, 37, e45-e53.	0.5	26
95	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	0.8	26
96	Inhibition of NF- κ B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. <i>Free Radical Biology and Medicine</i> , 2011, 51, 2249-2258.	1.3	25
97	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 765-772.	3.2	25
98	When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. <i>European Urology</i> , 2021, 79, 565-567.	0.9	25
99	Suppression of NF- κ B Activity by Parthenolide Induces X-Ray Sensitivity through Inhibition of Split-Dose Repair in TP53 Null Prostate Cancer Cells. <i>Radiation Research</i> , 2009, 171, 389-396.	0.7	24
100	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	0.9	23
101	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016, 117, E20-8.	1.3	22
102	Association between CD8 and PD-1 expression and outcomes after radical prostatectomy for localized prostate cancer. <i>Prostate</i> , 2021, 81, 50-57.	1.2	22
103	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 352-358.	0.5	21
104	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. <i>American Journal of Medicine</i> , 2015, 128, 609-616.	0.6	21
105	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
106	Evaluation of nuclear factor κ B and chemokine receptor CXCR4 expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. <i>BJU International</i> , 2011, 108, E51-8.	1.3	20
107	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. <i>Urology</i> , 2014, 83, 1316-1321.	0.5	17
108	Approach to Oligometastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 119-129.	1.8	17

#	ARTICLE	IF	CITATIONS
109	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 57.e15-57.e22.	0.8	17
110	Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. <i>European Urology Oncology</i> , 2019, 2, 475-482.	2.6	17
111	Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 348-348.	0.8	17
112	Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. <i>Cancer Detection and Prevention</i> , 2002, 26, 238-244.	2.1	16
113	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	2.0	16
114	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 50\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016, 87, 125-132.	0.5	16
115	Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.. <i>Journal of Clinical Oncology</i> , 2020, 38, 162-162.	0.8	16
116	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 72-82.	1.0	16
117	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2237-2247.	3.2	16
118	Cabozantinib Inhibits Abiraterone's Upregulation of IGF1R Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. <i>Clinical Cancer Research</i> , 2015, 21, 5578-5587.	3.2	15
119	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. <i>Clinical Cancer Research</i> , 2016, 22, 2183-2189.	3.2	15
120	NF- κ B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. <i>Cell Death Discovery</i> , 2018, 4, 10.	2.0	15
121	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 130-134.	0.9	15
122	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016, 118, 279-285.	1.3	14
123	Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 9-18.	2.5	14
124	Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.. <i>Journal of Clinical Oncology</i> , 2020, 38, 386-386.	0.8	14
125	ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 588-90.	0.3	14
126	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 330.e19-330.e25.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.2	13
128	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018, 131, 517-523.	0.6	13
129	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	0.8	13
130	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	1.6	13
131	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 182-182.	0.8	13
132	Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16 transgenic mice. <i>Drug Development Research</i> , 2019, 80, 824-830.	1.4	12
133	A reproducible approach to high-throughput biological data acquisition and integration. <i>PeerJ</i> , 2015, 3, e791.	0.9	12
134	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	1.3	12
135	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	0.8	12
136	Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5070-5070.	0.8	12
137	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e299-e305.	0.9	11
138	Impact of baseline serum IL-6 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). <i>Prostate</i> , 2020, 80, 1429-1437.	1.2	11
139	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021, 4, e2116536.	2.8	11
140	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	0.5	11
141	Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 1977-1982.	0.8	10
142	Diagnosis and Treatment of Testicular Cancer. <i>Surgical Pathology Clinics</i> , 2015, 8, 717-723.	0.7	10
143	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	2.3	10
144	Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. <i>BJU International</i> , 2016, 118, 919-926.	1.3	10

#	ARTICLE	IF	CITATIONS
145	Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. <i>European Urology Focus</i> , 2017, 3, 621-628.	1.6	10
146	A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 441-448.	1.1	9
147	Management of Metastatic Hormone-Sensitive Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 14.	1.0	9
148	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 80-88.	0.3	9
149	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
150	NF- κ B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. <i>Molecular Cancer Research</i> , 2021, 19, 1137-1145.	1.5	9
151	Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5009-5009.	0.8	9
152	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	0.9	8
153	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	1.3	8
154	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	2.0	8
155	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	1.1	8
156	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 341-348.	2.0	8
157	Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. <i>Journal of Surgical Research</i> , 2007, 143, 169-176.	0.8	7
158	Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 33-40.e4.	0.9	7
159	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 563-569.e3.	0.9	7
160	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	0.9	7
161	[¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. <i>Translational Oncology</i> , 2015, 8, 147-153.	1.7	6
162	AYA testis cancer: The unmet challenge. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27796.	0.8	6

#	ARTICLE	IF	CITATIONS
163	Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. <i>BJU International</i> , 2019, 123, 385-387.	1.3	6
164	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq0 0 0,rgBT /Overlock 10 T LBA2-LBA2.	0.8	6
165	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 314-319.	2.0	6
166	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5081-5081.	0.8	6
167	Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 649-661.	1.7	5
168	DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. <i>Radiation Research</i> , 2019, 192, 231.	0.7	5
169	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 683-693.	1.2	5
170	Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2019, 37, 86-86.	0.8	5
171	CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. <i>European Journal of Radiology</i> , 2016, 85, 1439-1444.	1.2	4
172	It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2016, 70, 263-264.	0.9	4
173	Chemotherapy for oligometastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 553-558.	0.9	4
174	A new standard-of-care for advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 592-593.	12.5	4
175	Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 78-84.	0.9	4
176	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 1053-1062.	1.2	4
177	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 32-37.	0.9	4
178	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2155-2162.	1.9	4
179	Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 98-98.	0.8	4
180	Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5057-5057.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Metastatic Prostate Cancer: In Search of More Granularity. <i>Journal of Clinical Oncology</i> , 2021, 39, 2968-2969.	0.8	4
182	Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 56-56.	0.8	4
183	A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5090-TPS5090.	0.8	4
184	CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS198-TPS198.	0.8	4
185	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
186	The role of chemotherapy in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 292-301.	0.9	4
187	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 377-387.	2.6	4
188	Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 111-113.	1.6	3
189	Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. <i>European Urology</i> , 2020, 77, 388-390.	0.9	3
190	A Call for Standardized Reporting of Adverse Events. <i>European Urology</i> , 2020, 78, 481-482.	0.9	3
191	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 199-207.	2.0	3
192	Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5018-5018.	0.8	3
193	HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHARTED Randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5020-5020.	0.8	3
194	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-43.	0.8	3
195	Body Mass Index and Outcomes in Germ-Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 283-290.	0.9	2
196	Selenomethionine induction of DNA repair response in human fibroblasts. , 0, .		2
197	Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16063-e16063.	0.8	2
198	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€”A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS385-TPS385.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 478-478.	0.8	2
200	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. Journal of Medical Internet Research, 2019, 21, e12044.	2.1	2
201	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 825-832.	0.4	2
202	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. Prostate, 2022, 82, 1176-1185.	1.2	2
203	Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, 5006-5006.	0.8	2
204	The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 2006, 176, S42-6.	0.2	1
205	Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2016, 2, 463-464.	1.6	1
206	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	0.8	1
207	Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?. European Urology, 2018, 74, 420-421.	0.9	1
208	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. , 2021, , .		1
209	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	1.7	1
210	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	0.8	1
211	Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 244-244.	0.8	1
212	Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. Journal of Clinical Oncology, 2019, 37, TPS343-TPS343.	0.8	1
213	Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHARTED trial (E3805).. Journal of Clinical Oncology, 2020, 38, 171-171.	0.8	1
214	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. Journal of Clinical Oncology, 2017, 35, 5080-5080.	0.8	1
215	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5062-5062.	0.8	1
216	The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 149-149.	0.8	1

#	ARTICLE	IF	CITATIONS
217	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€”A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5103-TPS5103.	0.8	1
218	Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. <i>Cancer Research</i> , 2022, 82, CT032-CT032.	0.4	1
219	Thymoma and Thymic Carcinoma. , 2006, , 237-256.		0
220	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, xi-xii.	0.9	0
221	The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2015, 1, 1270.	3.4	0
222	The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. <i>European Urology</i> , 2019, 76, 729-731.	0.9	0
223	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 82-82.	0.8	0
224	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 121-121.	0.8	0
225	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€”A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS266-TPS266.	0.8	0
226	Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5076-5076.	0.8	0
227	Use of elevated baseline IL-8, CCL-2, and TNFÎ± to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 13-13.	0.8	0
228	Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 191-191.	0.8	0
229	Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16515-e16515.	0.8	0
230	Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16508-e16508.	0.8	0
231	Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16601-e16601.	0.8	0
232	CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5591-TPS5591.	0.8	0
233	Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 153-153.	0.8	0
234	Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-415.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Causes and patterns of mortality in patients with lethal germ cell tumor (GCT).. Journal of Clinical Oncology, 2020, 38, 421-421.	0.8	0
236	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
237	Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.. Journal of Clinical Oncology, 2020, 38, 30-30.	0.8	0
238	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 58-58.	0.8	0
239	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 174-174.	0.8	0
240	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 402-402.	0.8	0
241	Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2011, 2011, 171-176.	1.8	0
242	Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).. Journal of Clinical Oncology, 2022, 40, 145-145.	0.8	0
243	Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.. Journal of Clinical Oncology, 2022, 40, 146-146.	0.8	0
244	Reply to L. Marandino et al. Journal of Clinical Oncology, 2022, , JCO2200497.	0.8	0